Table 1.
Patient characteristics and hematologic response.
| Variable | IgM Amyloidosis (n=38) |
|---|---|
| Age, median (range) | 61 (40-70) |
| Male | 27 (71) |
| Organ involved | |
| Cardiac | 10 (26) |
| Renal | 24 (63) |
| >2 | 5 (13) |
| Light Chain Type | |
| Lambda | 20 (53) |
| Kappa | 13 (34) |
| Biclonal | 5 (13) |
| Bone marrow findings | |
| % involvement, median (range) | 8 (1-50) |
| Lymphoplasmacytic features, n (%) | 17 (45) |
| dFLC, mg/dL, median (IQR) | 6.2 (2.3-16.1) |
| Serum M protein g/dL, median (IQR) | 0.9 (0.5-1.4) |
| Creatinine, median (IQR) | 1 (0.9-1.3) |
| Urine protein*, g/24hrs, median (range) | 5.1 (1.7-34.9) |
| NT-proBNP+, pg/ml, median (range) | 1567 (576-12983) |
| Mayo Stage 2004, % | |
| Stage I/II/III | 87/6/6 |
| Missing, n | 7 |
| Mayo Stage 2012, n (%) | |
| Stage I/II/III/IV | 74/11/7/7 |
| Missing, n | 11 |
| Prior therapy, n (%) | 22 (58) |
| Number prior therapies, median (range) | 1 (1-5) |
| Corticosteroid only | 4 (11) |
| Chemotherapy | 5 (13) |
| Proteasome inhibitor | 7 (18) |
| Chemoimmunotherapy | 8 (21) |
| Single agent Rituximab | 3 (8) |
| Conditioning | |
| Melphalan 200 | 24 (63) |
| Melphalan 140 | 8 (21) |
| BEAM | 6 (16) |
| Hematologic Response, n (%) | |
| CR | 7 (18) |
| VGPR | 22 (58) |
| PR | 6 (16) |
| NR | 3 (8) |
Abbreviations: IQR, interquartile range; dFLC, difference between involved and uninvolved light chains; BEAM, carmustine, etoposide, cytarabine and melphalan; CR, complete response; VGPR, very good partial response; PR, partial response; NR, no response.
*
amongst patients with renal involvement.
+
amongst patients with cardiac involvement.